Swiss drugmaker Novartis on Friday won US approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
This content got low rating by people.
Novartis $2m gene therapy for rare disorder is world's most expensive drug
Words
0
Reading
0 min
Listen
Play
2019-05-25 22:01